Bcl-2 Antisense Drug - Biotech, Pharma and Life Science Channel
PubMed Articles
Antisense oligonucleotides (oligos) have been employed against prostate cancer models in both in vivo and in vitro systems. While most target growth factors or their receptors, other oligos are direct...
The aim of the study is to evaluate the efficacy and safety of a three-drug chemotherapy regimen including gemcitabine, carboplatin, and paclitaxel as induction therapy in clinical stage III non-small...
Developing technologies to unlock the therapeutic and research potential of human stem cells.
Since human embryonic stem cells (hESCs) were first isolated and cultured nearly 15 years ago, stem cell biology has been a promising and fast-moving area of research. Improved clinical predictivity i...
Interstitial drug delivery is a promising technique for glioma treatment; however, suboptimal methodologies limit the ability to document the delivery of therapeutic agents. The present study employed...
Tuberculosis (TB) disease is treated in most cases with a regimen of several drugs taken for 6-9 months. Currently, 10 drugs are approved by the Food and Drug Administration (FDA) for treatment of TB....
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) tested bexarotene as a potential β-amyloid-lowering drug for Alzheimer's disease (AD). We were not able to reproduce...
Apolipoprotein C-III: Going Back to the Future for a Lipid Drug Target.
The HMG-CoA reductase inhibitors are a class of drugs also known as statins. These drugs are effective and widely prescribed for the treatment of hypercholesterolemia and prevention of cardiovascular...
Artemisinin, a poorly water-soluble antimalarial drug, presents a low and erratic bioavailability upon oral administration. The aim of this work was to study an agglomerated powder dosage form for ora...
News Articles
Anti-Cancer Drug Reverses Alzheimer's Disease In Mice
An anti-cancer drug may reverse memory problems in an Alzheimer's Disease mouse model, according to new research carried out at the University of Pittsburgh Graduate School of Public Health. The study...
Prosensa B.V. (Leiden, the Netherlands) filed to raise up to $60 million in an IPO on NASDAQ underwritten by JPMorgan; Citigroup; Leerink; Wedbush; and KBC Securities. Last month, partner GlaxoSmithKl...
Bausch & Lomb's Ista pleads guilty over kickbacks
By Jonathan Stempel (Reuters) - Ista Pharmaceuticals Inc pleaded guilty on Friday to charges it used kickbacks and improper marketing to boost sales of a drug meant to treat eye pain and agreed to pay...
Exelixis Prepares For ASCO 2013, Stock Stays Rangebound
By Brian L. Wilson:One of the biopharmaceutical companies that has been lagging the stellar performance of its peers is Exelixis (EXEL), developer of the compound cabozantinib. Cabo, which was FDA app...
Studies cast doubt on cancer drug as Alzheimer’s treatment
Bexarotene, a cancer drug touted as a potential treatment for Alzheimer’s disease, may not be the blockbuster remedy scientists were hoping for, according to several analyses published in Science on...
J&J investor day: A club drug for depression and an Alzheimer's pledge
Johnson & Johnson sees great potential in a club drug to treat depression, isn’t giving up on treating Alzheimer’s disease and is investing heavily in immunotherapy for cancer....
FDA panel backs Merck insomnia drug, but cites safety concerns
The US Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee has recommended Merck’s insomnia drug suvorexant when given in low dosages, [...]
FDA panel backs Merck insomnia drug, but warns of safety concerns
An FDA panel might have given its backing to Merck’s insomnia drug suvorexant, but this may not signal the end for the pharmaceutical giant’s sleepless [...]
The Patient Role in Stimulating Chronic Fatigue Syndrome Drug Development
The Food & Drug Administration convened a two-day meeting with CFS patients, advocates, clinicians and researchers in late April. One of the speakers invited by FDA was former Lilly corporate stra...
FDA allows marketing of first A1c test labeled for diagnosing diabetes, from Roche
The US Food and Drug Administration yesterday (May 23) announced that it is allowing marketing of the Cobas Integra 800 Tina-quant HbA1cDx assay (Tina-quant HbA1cDx assay) for the diagnosis of diabete...
Events
None
Companies
Bio-Path is developing a patented, liposomal drug delivery system and products developed at The University of Texas M. D. Anderson Cancer Center, with two clinical cancer drug can...
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The companyâs lead drug candidate, TOK-001, is the first i...
Certara is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focu...
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research...
Circadian Technologies Limited
Circadian Technologies Limited is an emerging leader in the field of angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs),...
Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells...
Elan Corporation, plc is a neuroscience-based biotechnology company focused on discovering and developing advanced therapies in neurodegeneration and autoimmune diseases, and real...
InSite Vision is an ophthalmic products company currently focused on ocular infection, glaucoma, and retinal disease. The Company specializes in three platform technologies: topical drug delivery (Dur...
FDB provides drug knowledge that helps healthcare professionals make precise medication-related decisions. With thousands of customers worldwide, FDB enables our information syste...
AAIPharma Services Corp. is a leading provider of contract services that support all phases of drug development. The company’s wide array of capabilities includes analytical chemistry, formula...
Clinical Trials
Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49
The purpose of this study is to test an investigational vaccine known as "VAX161C." An "investigational" vaccine is one that is not licensed for commercial use in the by the United States...
The objective of the study is To verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent in the treatment of de novo lesions in native coronary arteries with a reference...
The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastri...
This study investigates safety and pharmacokinetic comparison of DWJ1276, a combination drug of Rosuvastatin and Olmesartan (test formulation), and co-administration of Rosuvastatin and Ol...
Drug Eluting Balloon Versus Drug Eluting Stent in PCI
Drug eluting balloons (DEB) have been developed to overcome the limitations of drug eluting stent (DES), but clinical results of different studies about DEB are not consistent. Thus, we p...
Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid.
A randomized, open-label, six-sequence, three-period, three-treatment, multiple dosing clinical trial to investigate the pharmacokinetic drug interaction between Pregabalin and Thioctic ac...
Exhale (R) Stent for Emphysema
Current treatment for emphysema is limited to measures that include inhaled oxygen, bronchodilators, anti-inflammatory drugs and pulmonary rehabilitation. Highly invasive procedures such...
A Research Study Examining the Use of Olanzapine for the Prevention of Migraine
Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The...
Hypothesis Nevirapine resistance developed in women and infants in the HIVNET 006 and 012 cohorts as a consequence of use of an agent with a long t½ as monotherapy in individuals with hi...
The purpose of this study is to determine if a drug called topiramate is safe and effective as an add-on therapy in the treatment of Obsessive-Compulsive Disorder (OCD). Topiramate is an...
Videos
Medical and Biotech [MESH] Definitions
Nontherapeutic Human Experimentation
Human experimentation that is not intended to benefit the subjects on whom it is performed. Phase I drug studies (CLINICAL TRIALS, PHASE I AS TOPIC) and research involving healthy volunteers are examples of nontherapeutic human experimentation.
Hyperuricemia
Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
Rna, Small Interfering
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
Metered Dose Inhalers
A medical device used to ensure the proper amount of medication is delivered for inhalation. Usually, it is a small aerosol canister placed in a plastic holder. When the canister is pressed, a calibrated amount of drug is released.
Histamine H1 Antagonists, Non-sedating
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment.
